Cite
Lázaro-Navarro J, Pimentel-Gutiérrez HJ, Gauert A, et al. Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation. Blood Adv. 2021;5(24):5501-5506doi: 10.1182/bloodadvances.2021004513.
Lázaro-Navarro, J., Pimentel-Gutiérrez, H. J., Gauert, A., Hagemann, A. I. H., Eisenschmid, J., Gökbuget, N., Vick, B., Jeremias, I., Seyfried, F., Meyer, L. H., Debatin, K. M., Richer, K., Bultman, M., Neumann, M., Hänzelmann, S., Serve, H., Astrahantseff, K., Rieger, M. A., Eckert, C., Baldus, C. D., & Bastian, L. (2021). Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation. Blood advances, 5(24), 5501-5506. https://doi.org/10.1182/bloodadvances.2021004513
Lázaro-Navarro, Juan, et al. "Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation." Blood advances vol. 5,24 (2021): 5501-5506. doi: https://doi.org/10.1182/bloodadvances.2021004513
Lázaro-Navarro J, Pimentel-Gutiérrez HJ, Gauert A, Hagemann AIH, Eisenschmid J, Gökbuget N, Vick B, Jeremias I, Seyfried F, Meyer LH, Debatin KM, Richer K, Bultman M, Neumann M, Hänzelmann S, Serve H, Astrahantseff K, Rieger MA, Eckert C, Baldus CD, Bastian L. Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation. Blood Adv. 2021 Dec 28;5(24):5501-5506. doi: 10.1182/bloodadvances.2021004513. PMID: 34610112; PMCID: PMC8714730.
Copy
Download .nbib